Scholarlink

Background <p>Lactic acid bacteria are increasingly being studied for their immunomodulatory activity and protective effects against pathogens. <i>Limosilactobacillus fermentum</i> DSM 34872, isolated from human breast milk, was evaluated for its prophylactic potential using <i>Galleria mellonella</i> as an alternative preclinical model. Results: The antimicrobial activity of <i>L. fermentum</i> against <i>Salmonella enterica</i> subsp. <i>enterica</i> serovar Typhimurium or <i>Enterococcus faecalis</i> was first assessed in vitro by the overlay assay. In vivo, <i>G. mellonella</i> larvae were orally administered with <i>L. fermentum</i> via gavage and exposed to pathogens. Survival rates, melanization score, and expression of immune-related genes (<i>dorsal, relish, gallerimycin, gloverin</i>) were evaluated in both the gut and hemolymph using RT-qPCR at 4 and 24 h after infection.</p> Conclusion <p><i>L. fermentum</i> showed antibacterial activity in vitro. In vivo, pre-treatment with <i>L. fermentum</i> significantly increased survival and delayed mortality. The melanization score supported the in vivo survival results. Gene expression analysis revealed modulation of key immune markers in both the gut and hemolymph, suggesting controlled immune activation rather than hyperinflammation in <i>L. fermentum</i> pretreated groups. Prophylactic oral administration of <i>L. fermentum</i> protected against lethal bacterial infections in <i>G. mellonella</i>, altering both local and systemic immune responses. These results highlight the potential of <i>L. fermentum</i> as a promising candidate for future in vivo analyses and confirm <i>G. mellonella</i> as an ethical, economical, and reliable preclinical model for preliminary screening, with the aim of subsequent evaluations in accredited clinical models.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Prophylactic oral Limosilactobacillus fermentum DSM 34872 protects Galleria mellonella from gut-associated pathogens

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月6日

查看全文
  • Antonio Guarnieri,
  • Noemi Venditti,
  • Natasha Brancazio,
  • Farwa Mukhtar,
  • Marilina Falcone,
  • Addis Temie Worku,
  • Maria Di Naro,
  • Giovanni Scapagnini,
  • Giulio Petronio Petronio,
  • Roberto Di Marco

摘要

Background

Lactic acid bacteria are increasingly being studied for their immunomodulatory activity and protective effects against pathogens. Limosilactobacillus fermentum DSM 34872, isolated from human breast milk, was evaluated for its prophylactic potential using Galleria mellonella as an alternative preclinical model. Results: The antimicrobial activity of L. fermentum against Salmonella enterica subsp. enterica serovar Typhimurium or Enterococcus faecalis was first assessed in vitro by the overlay assay. In vivo, G. mellonella larvae were orally administered with L. fermentum via gavage and exposed to pathogens. Survival rates, melanization score, and expression of immune-related genes (dorsal, relish, gallerimycin, gloverin) were evaluated in both the gut and hemolymph using RT-qPCR at 4 and 24 h after infection.

Conclusion

L. fermentum showed antibacterial activity in vitro. In vivo, pre-treatment with L. fermentum significantly increased survival and delayed mortality. The melanization score supported the in vivo survival results. Gene expression analysis revealed modulation of key immune markers in both the gut and hemolymph, suggesting controlled immune activation rather than hyperinflammation in L. fermentum pretreated groups. Prophylactic oral administration of L. fermentum protected against lethal bacterial infections in G. mellonella, altering both local and systemic immune responses. These results highlight the potential of L. fermentum as a promising candidate for future in vivo analyses and confirm G. mellonella as an ethical, economical, and reliable preclinical model for preliminary screening, with the aim of subsequent evaluations in accredited clinical models.